Upon applying the PICOS criteria, 94 articles were included; of these, 76 articles reported the prevalence of HER2 mutation and/or amplification, and 18 articles were prospective clinical trials evaluating the efficacy of treatment in NSCLC patients with HER2 mutations or amplification (Figure 2). Here, ERBB2 is linked to non-small cell lung carcinoma.